MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 2, 2008; DOI: 10.1124/mol.107.041053


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.041053v1
73/4/1213    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Colleen M. Niswender
Kari A. Johnson
Qingwei Luo
Jennifer E. Ayala
P. Jeffrey Conn
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niswender, C. M.
Right arrow Articles by Weaver, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niswender, C. M.
Right arrow Articles by Weaver, C. D.


Received for publication August 20, 2007.
Revised December 31, 2007.
Accepted for publication December 31, 2007.

A novel assay of Gi/o-linked G protein coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors

Colleen M. Niswender 1*, Kari A. Johnson 1, Qingwei Luo 1, Jennifer E. Ayala 1, Caroline Kim 1, P. Jeffrey Conn 1, C. David Weaver 1

1 Vanderbilt University Medical Center

* Address correspondence to: E-mail: colleen.niswender{at}vanderbilt.edu

Abstract

The group III metabotropic glutamate receptors (mGluRs) represent a family of presynaptically expressed GPCRs with enormous therapeutic potential; however, robust cellular assays to study their function have been difficult to develop. We present here a new assay, compatible with traditional high throughput screening platforms, to detect activity of pharmacological ligands interacting with Gi/o-coupled GPCRs including the group III mGluRs 4, 7 and 8. The assay takes advantage of the ability of the G{beta}{gamma} subunits of Gi and Go heterotrimers to interact with GIRK potassium channels and we show here that we are able to detect the activity of multiple types of pharmacophores including agonists, antagonists, and allosteric modulators of several distinct GPCRs. Using GIRK-mediated thallium flux, we perform a side-by-side comparison of the activity of a number of commercially available compounds, some of which have not been extensively evaluated due to the previous lack of robust assays, at each of the three major group III mGluRs. Interestingly, several compounds previously considered to be general group III mGluR antagonists have very weak activity using this assay, suggesting the possibility that these compounds may not effectively inhibit these receptors in native systems. We anticipate that the GIRK-mediated thallium flux strategy will provide a novel tool to advance the study of Gi/o-coupled GPCR biology and promote ligand discovery and characterization.


Key words: Metabotropic glutamate, Gi family, Fluorescence techniques





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics